Related Articles
Chemotherapy, IL-12 gene therapy and combined adjuvant therapy of HPV 16-associated MHC class I-proficient and -deficient tumours
Immunization with MHC class I-negative but not -positive HPV16-associated tumour cells inhibits growth of MHC class I-negative tumours
NK1.1+ cells are important for the development of protective immunity against MHC I-deficient, HPV16-associated tumours
CpG oligodeoxynucleotides are effective in therapy of minimal residual tumour disease after chemotherapy or surgery in a murine model of MHC class I-deficient, HPV16-associated tumours
Immune escape phenotype of HPV16-associated tumours: MHC class I expression changes during progression and therapy